An assessment of Half-Inderal LA and Inderal LA in the treatment of hypertension in elderly subjects.
Twenty-three elderly hypertensive patients, who remained hypertensive despite treatment with 2.5 mg bendrofluazide once daily, were randomised to receive, in addition to the diuretic, placebo, or a low-dose (80 mg) or a high-dose (160 mg) of long-acting propranolol once daily in a double-blind crossover study. Each randomised treatment period was of four weeks' duration. Blood pressure was assessed in the supine and standing positions, as well as after an individualised exercise test. Evaluations were carried out at least 24 hours after the last dose of medication. Sitting blood pressure fell from 196.2 +/- 21.3/107.2 +/- 11.3 mmHg to 193.1 +/- 17.5/106.0 +/- 15.9 mmHg for bendrofluazide alone, 193.2 +/- 24.76/97.3 +/- 11.9 mmHg for bendrofluazide plus long-acting propranolol (80 mg) and 187.2 +/- 19.6/102.1 +/- 11.2 mmHg for bendrofluazide plus long-acting propranolol (160 mg). The three randomised treatments yielded standing pressures of 191.3 +/- 20.5/106.2 +/- 13.5 mmHg, 192.4 +/- 29.0/99.6 +/- 12.6 mmHg and 192.4 +/- 28.0/106.0 +/- 8.6 mmHg for bendrofluazide alone, and bendrofluazide plus low- and high-dose, long-acting propranolol respectively, compared with the pretreatment standing blood pressure of 193.4 +/- 18.4/108.4 +/- 14.8 mmHg. There appeared to be no significant effect of any treatment on systolic blood pressures in either sitting or standing positions. No statistically significant differences between the three randomised treatments with regard to post-exercise diastolic pressure were observed, except for a small but significantly greater reduction during treatment with the low-dose, long-acting propranolol compared with the high-dose, long-acting propranolol.(ABSTRACT TRUNCATED AT 250 WORDS)
Datta
S R
SR
D000368:Aged; D001539:Bendroflumethiazide / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D011433:Propranolol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D003692:Delayed-Action Preparations; D001539:Bendroflumethiazide; D011433:Propranolol